Express News | Astria Therapeutics Inc : H.c. Wainwright Cuts Target Price to $16 From $18
Moomoo 24/7Apr 23 06:14 ET
In the Wake of Astria Therapeutics, Inc.'s (NASDAQ:ATXS) Latest US$51m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions
Key Insights Given the large stake in the stock by institutions, Astria Therapeutics' stock price might be vulnerable to their trading decisions 52% of the business is held by the top 7 shareholders
Simply Wall StApr 11 10:28 ET
Astria Therapeutics Appoints Sunil Agarwal to Its Bd of Directors
Astria Therapeutics Appoints Sunil Agarwal to Its Bd of Directors
Dow JonesApr 9 08:01 ET
Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS)
Yahoo FinanceApr 3 19:00 ET
Astria Therapeutics Inc(ATXS.US) Officer Sells US$135.94K in Common Stock
$Astria Therapeutics Inc(ATXS.US)$ Officer Morabito Christopher sold 10,000 shares of Common Stock on Apr 1, 2024 at an average price of $13.5939 for a total value of $135.94K.Source: Announcement Wha
moomoo NewsApr 3 16:47 ET
Form 144 | Astria Therapeutics Inc(ATXS.US) Officer Proposes to Sell 135.94K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Astria Therapeutics Inc(ATXS.US)$ Officer CHRIS MORABITO intends to sell 10,000 shares of its common stock on Apr 1, with a total market value of approximately $135.94K
moomoo NewsApr 1 17:13 ET
Astria Therapeutics Price Target Raised to $22.00/Share From $17.00 by Wedbush
Astria Therapeutics Price Target Raised to $22.00/Share From $17.00 by Wedbush
Dow JonesMar 26 09:44 ET
Express News | Wedbush Maintains Outperform on Astria Therapeutics, Raises Price Target to $22
Moomoo 24/7Mar 26 09:34 ET
Astria Therapeutics Is Maintained at Buy by Jefferies
Astria Therapeutics Is Maintained at Buy by Jefferies
Dow JonesMar 26 07:29 ET
Astria Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Astria Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 25 12:45 ET
Express News | HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Maintains $18 Price Target
Moomoo 24/7Mar 25 12:35 ET
Express News | Astria Therapeutics Shares Are Trading Higher After the Company Announced Initial Proof-of-concept Results From the ALPHA-STAR Phase 1b/2 Clinical Trial Evaluating STAR-0215 in HAE Patients
Moomoo 24/7Mar 25 08:43 ET
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results From the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
-- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in
BusinesswireMar 25 07:30 ET
Astria Therapeutics Down Over 13%, on Pace for Largest Percent Decrease Since June 2022 -- Data Talk
Astria Therapeutics, Inc. ( ATXS ) is currently at $14.49, down $2.20 or 13.18% --Would be lowest close since March 12, 2024, when it closed at $14.48 --On pace for largest percent decrease since Ju
Dow JonesMar 20 13:26 ET
Astria Therapeutics Price Target Maintained With a $17.00/Share by Wedbush
Astria Therapeutics Price Target Maintained With a $17.00/Share by Wedbush
Dow JonesMar 5 08:44 ET
Express News | HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $18 Price Target
Moomoo 24/7Mar 5 07:04 ET
Astria TherapeuticS GAAP EPS of -$2.42 Misses by $0.19
Seeking AlphaMar 4 16:37 ET
Astria Therapeutics 4Q Loss/Shr 86c >ATXS
Astria Therapeutics 4Q Loss/Shr 86c >ATXS
Dow JonesMar 4 16:21 ET
Express News | Astria Therapeutics Q4 EPS $(0.86) Down From $(0.72) YoY
Moomoo 24/7Mar 4 16:20 ET
Astria Therapeutics Expects Cash, Cash Equivalents and Short-Term Investments With Proceeds From Financing Activity Will Be Sufficient to Fund Ops Into Mid-2027 >ATXS
Astria Therapeutics Expects Cash, Cash Equivalents and Short-Term Investments With Proceeds From Financing Activity Will Be Sufficient to Fund Ops Into Mid-2027 >ATXS
Dow JonesMar 4 16:20 ET
No Data
No Data